A. John Orwin's most recent trade in CARGO Therapeutics Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 9,365 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 0 | - | - | Restricted Stock Unit | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 35,375 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 2,600 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 3,335 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 2,035 (0%) | 0% | 0 | Common Stock | |
| CARGO Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,742 | 23,742 | - | - | Stock Option (Right to Buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 28,875 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Apr 2024 | 1 | 1 | - | 0 | Series A Junior Preferred Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | A. John Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 01 Sep 2023 | 22,951 | 77,541 (0%) | 0% | 0.4 | 8,597 | Class A Common Stock |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 2,044 | 31,047 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 435,000 | 435,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.78 per share. | 02 Sep 2022 | 20,908 | 100,492 (0%) | 0% | 1.8 | 37,116 | Class A Common Stock |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 260,000 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 241,000 | 241,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 241,000 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 148,754 | 148,754 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 148,754 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 58,995 | 58,995 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 58,995 | 0 | - | - | Employee stock option (right to buy) | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 3,676 | 3,676 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 1,503 | 29,003 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 17,875 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2021 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2021 | 115,400 | 121,400 (0%) | 0% | 0 | Class A Common Stock | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,462 | 3,462 | - | - | Non-Qualified Stock Option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 14,875 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 1,402 | 27,500 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc - Ordinary Shar... | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) |